Introduction: Exposure to potential drug-drug interactions (pDDIs) can be a notable source of avoidable drug-related harm that requires adequate management to prevent medical errors. We aimed to evaluate pDDIs and associated factors in hospitalized urological patients on admission, during hospitalization, and on discharge. Methods: A retrospective cohort study was conducted at the Clinic of Urology of the University Clinical Centre Kragujevac, Serbia. To detect pDDIs, we used Lexicomp, which categorizes pDDIs as follows: X (avoid combination), D (consider therapy modification), C (monitor therapy), B (no action needed), and A (no known interaction). Multiple linear regression analysis was used to identify factors associated with the number of pDDIs. Results: More than half of the 220 included patients had at least one pDDI on admission and discharge (57.3% and 63.6%, respectively), whereas 95.0% had at least one pDDI during hospitalization. The total number and number of X, D, C, and B categories of pDDIs were the highest during hospitalization and the lowest on admission. Duration of hospitalization, arrhythmias, dementia, renal failure, cancer, surgery during hospitalization, number of prescribed drugs, and various pharmacological drug classes were risk factors for a higher number of pDDIs, while age, ischemic heart disease, hypertension, and development of infection during hospitalization were protective factors in at least one of the stages. The impact of renal colic depended on the stage and category of pDDI. Conclusion: More than half of the urological patients were exposed to at least one pDDIs at all stages. Medical professionals should regularly screen for pDDIs, particularly in patients with risk factors.

1.
Scheife
RT
,
Hines
LE
,
Boyce
RD
,
Chung
SP
,
Momper
JD
,
Sommer
CD
, et al
.
Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support
.
Drug Saf
.
2015
;
38
(
2
):
197
206
.
2.
Amjadi
M
,
Hemmati Ghavshough
M
,
Mokhtari
R
,
Mohammad-Rahimi
M
.
Evaluation of general practitioners’ awareness of common urological interventions
.
J Res Urol
.
2020
;
4
(
2
):
92
100
.
3.
Buğday
MS
,
Öksüz
E
.
Drug-drug interactions in the risky population: elderly, urological patients admitted to the intensive care unit
.
East J Med
.
2021
;
26
(
2
):
236
41
.
4.
Noor
S
,
Ismail
M
,
Khan
F
.
Potential drug-drug interactions in patients with urinary tract infections: a contributing factor in patient and medication safety
.
Front Pharmacol
.
2019
;
10
:
1032
.
5.
Jamani
R
,
Lee
EK
,
Berry
SR
,
Saluja
R
,
DeAngelis
C
,
Giotis
A
, et al
.
High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate
.
Eur J Clin Pharmacol
.
2016
;
72
(
11
):
1391
9
.
6.
Bonnet
C
,
Boudou-Rouquette
P
,
Azoulay-Rutman
E
,
Huillard
O
,
Golmard
JL
,
Carton
E
, et al
.
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
.
Cancer Chemother Pharmacol
.
2017
;
79
(
5
):
1051
5
.
7.
Benoist
GE
,
van Oort
IM
,
Smeenk
S
,
Javad
A
,
Somford
DM
,
Burger
DM
, et al
.
Drug-drug interaction potential in men treated with enzalutamide: mind the gap
.
Br J Clin Pharmacol
.
2018
;
84
(
1
):
122
9
.
8.
Vicente-Valor
J
,
Escudero-Vilaplana
V
,
Collado-Borrell
R
,
Pérez-Ramírez
S
,
Villanueva-Bueno
C
,
Narrillos-Moraza
Á
, et al
.
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice
.
Expert Opin Drug Metab Toxicol
.
2021
;
17
(
12
):
1467
73
.
9.
Appukkuttan
S
,
Ko
G
,
Fu
C
,
Bannister
B
,
Kong
SX
,
Jhaveri
J
, et al
.
Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors
.
Expert Rev Anticancer Ther
.
2024
;
24
(
5
):
325
33
.
10.
WHO Collaborating Centre for Drug Statistics Methodology
.
WHOCC - ATC/DDD Index. 2023. [cited 2023 Dec 29]. Available from:
https://www.whocc.no/atc_ddd_index/
11.
Vonbach
P
,
Dubied
A
,
Krähenbühl
S
,
Beer
JH
.
Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine
.
Eur J Intern Med
.
2008
;
19
(
6
):
413
20
.
12.
Ranković
A
,
Milentijevic
I
,
Jankovic
S
.
Factors associated with potential drug-drug interactions in psychiatric inpatients
.
Eur J Hosp Pharm
.
2024
;
31
(
2
):
127
34
.
13.
Dagnew
EM
,
Ergena
AE
,
Wondm
SA
,
Sendekie
AK
.
Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia
.
BMC Pharmacol Toxicol
.
2022
;
23
(
1
):
88
.
14.
Hamadouk
RM
,
Alshareif
EM
,
Hamad
HM
,
Yousef
BA
.
The prevalence and severity of potential drug-drug interactions in internal medicine ward at soba teaching hospital
.
Drug Healthc Patient Saf
.
2023
;
15
:
149
57
.
15.
Janković
SM
,
Pejčić
AV
,
Milosavljević
MN
,
Opančina
VD
,
Pešić
NV
,
Nedeljković
TT
, et al
.
Risk factors for potential drug-drug interactions in intensive care unit patients
.
J Crit Care
.
2018
;
43
:
1
6
.
16.
Straubhaar
B
,
Krähenbühl
S
,
Schlienger
RG
.
The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge
.
Drug Saf
.
2006
;
29
(
1
):
79
90
.
17.
Marchbanks
CR
.
Drug-drug interactions with fluoroquinolones
.
Pharmacotherapy
.
1993
;
13
(
2P2
):
23S
28S
.
18.
Mar
PL
,
Horbal
P
,
Chung
MK
,
Dukes
JW
,
Ezekowitz
M
,
Lakkireddy
D
, et al
.
Drug interactions affecting antiarrhythmic drug use
.
Circ Arrhythm Electrophysiol
.
2022
;
15
(
5
):
e007955
.
19.
Milosavljevic
MN
,
Kocovic
AG
,
Jankovic
SM
,
Radovanovic
DM
,
Milisavljevic
SS
,
Stefanovic
SM
.
Risk factors for the occurrence of potential drug-drug interactions in surgical patients
.
Ser J Exp Clin Res
.
2021
;
22
(
3
):
213
23
.
20.
Pejčić
AV
,
Janković
SM
,
Davidović
G
.
Drug–drug interactions in patients with acute coronary syndrome across phases of treatment
.
Intern Emerg Med
.
2019
;
14
(
3
):
411
22
.
21.
Lanas
A
,
Benito
P
,
Alonso
J
,
Hernández-Cruz
B
,
Barón-Esquivias
G
,
Perez-Aísa
Á
, et al
.
Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)
.
Reumatol Clin
.
2014
;
10
(
2
):
68
84
.
22.
May
M
,
Schindler
C
.
Clinically and pharmacologically relevant interactions of antidiabetic drugs
.
Ther Adv Endocrinol Metab
.
2016
;
7
(
2
):
69
83
.
23.
Shahid
H
,
Singh
JA
.
Investigational drugs for hyperuricemia
.
Expert Opin Investig Drugs
.
2015
;
24
(
8
):
1013
30
.
24.
Ben Ghezala
I
,
Luu
M
,
Bardou
M
.
An update on drug–drug interactions associated with proton pump inhibitors
.
Expert Opin Drug Metab Toxicol
.
2022
;
18
(
5
):
337
46
.
25.
Sönnerstam
E
,
Sjölander
M
,
Lövheim
H
,
Gustafsson
M
.
Clinically relevant drug–drug interactions among elderly people with dementia
.
Eur J Clin Pharmacol
.
2018
;
74
(
10
):
1351
60
.
26.
Santos-Díaz
G
,
Pérez-Pico
AM
,
Suárez-Santisteban
,
García-Bernalt
V
,
Mayordomo
R
,
Dorado
P
.
Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a Spanish hospital
.
Pharmaceutics
.
2020
;
12
(
8
):
713
.
27.
Waisel
DB
.
Vulnerable populations in healthcare
.
Curr Opin Anaesthesiol
.
2013
;
26
(
2
):
186
92
.
28.
Avershina
E
,
Shapovalova
V
,
Shipulin
G
.
Fighting antibiotic resistance in hospital-acquired infections: current state and emerging technologies in disease prevention, diagnostics and therapy
.
Front Microbiol
.
2021
;
12
:
707330
.
29.
Folic
MM
,
Jankovic
SM
.
Factors affecting outcome in hospitalized patients treated according to recommendations from clinical pharmacologists
.
Int J Clin Pharmacol Ther
.
2023
;
61
(
8
):
339
45
.
30.
Dunn
SP
,
Holmes
DR
,
Moliterno
DJ
.
Drug-drug interactions in cardiovascular catheterizations and interventions
.
JACC Cardiovasc Interv
.
2012
;
5
(
12
):
1195
208
.
You do not currently have access to this content.